This study showed that CAR-mediated signaling could significantly improve the ability of CAR-iMac to engulf tumor cells and lead to the transformation of CAR-iMac from M2 to M1 type in the presence of specific antigens such as CD19.68 In 2020, the FDA approved a Phase I clinical trial, NCT04660929, aimed at treating tumor patients with relapsed/refractory HER2 over-expression with anti-HER2 CAR macrophages (CT-0508, CARISMA Therapeutics). The gene discussed is CD19; the disease is neoplasm.